Results 81 to 90 of about 2,530 (165)
Bilateral blindness after uneventful brolucizumab injection for macular degeneration
BMC Ophthalmology, 2022 Background We report a very severe case of bilateral panuveitis and ischemic vasculitis with possible perineural inflammation, which followed bilateral intravitreal brolucizumab administration in a patient with neovascular age-related macular ...
Ilan Barchichat +3 more
doaj +1 more source
The initial results of using brolucizumab (Beovu®), an angiogenesis inhibitor, for choroidal neovascularization in patients with age-related macular degeneration [PDF]
Клиническая офтальмология, 2022 N.S. Zhayvoronok1, O.V. Kolenko1–3, L.P. Danilova1,2, E.L. Sorokin1,3 1Khabarovsk Branch of the S. Fedorov Eye Microsurgery Federal State Institution, Khabarovsk, Russian Federation 2Institute of Advanced Training of Healthcare Specialists ...
N.S. Zhayvoronok +3 more
doaj
Acta Ophthalmologica, Volume 103, Issue 1, Page 99-108, February 2025.Abstract Purpose To analyse the impact on cost if faricimab is used as the first‐line treatment for neovascular age‐related macular degeneration (nAMD) compared to standard treatment with bevacizumab. Methods Retrospective registry study including real‐world data from the Swedish Macula Registry between 2017 and 2022.
Souad Abdalla +3 more
wiley +1 more source
Intravitreal Bevacizumab in Neovascular Age-Related Macular Degeneration as First Choice: a New Italian Ruling [PDF]
, 2020 Background: Intravitreal vascular endothelial growth factor (VEGF) inhibitors represent the mainstay of neovascular age-related macular degeneration (nAMD) treatment.
Casalino, Giuseppe +2 more
core +2 more sources
Clinical and Translational Science, Volume 18, Issue 1, January 2025.ABSTRACT Monoclonal antibodies (mAbs) are critical components in the therapeutic landscape, but their dosing strategies often evolve post‐approval as new data emerge. This review evaluates post‐marketing label changes in dosing information for FDA‐approved mAbs from January 2015 to September 2024, with a focus on both initial and extended indications ...
Nai Lee +6 more
wiley +1 more source
Clinical Ophthalmology, 2023 Debdulal Chakraborty,1 Milan Thakkar,2 Ramesh Venkatesh,3 Sangeeta Roy,4 Maulik Bhavsar,5 Helene Karcher6 1Disha Eye Hospital, Kolkata, West Bengal, India; 2Dr.
Chakraborty D +5 more
doaj
Acta Ophthalmologica, Volume 102, Issue 8, Page 953-962, December 2024.Abstract Purpose To report the incidence of post‐injection endophthalmitis (PIE) and the cumulative risk associated with repeated injections of intravitreal anti‐vascular endothelial growth factor (anti‐VEGF). Methods We employed nationwide registries in Denmark to include all individuals aged ≥40 years who received at least one intravitreal anti‐VEGF ...
Benjamin Sommer Thinggaard +6 more
wiley +1 more source
Brolucizumab and Platelet Activation and Reactivity [PDF]
\ua9 2025 The Author(s). Published with license by Taylor & Francis Group, LLC. Purpose: This study explores the potential interaction of brolucizumab with platelets and its effects on platelet activation and reactivity, crucial in retinal vasculitis
Bieber K +6 more
core
Functional and anatomical outcomes of brolucizumab for nAMD in a real-life setting [PDF]
To report long-term outcomes of brolucizumab in neovascular age-related macular degeneration (nAMD) treatment. Records from 74 patients were retrospectively reviewed. Both naïve eyes and those previously treated with other antiVEGF agents were included.
Cirigliano, Gabriella +3 more
core +1 more source
Clinical &Experimental Ophthalmology, Volume 52, Issue 8, Page 853-860, November 2024.Abstract Background Patients in rural Australia have limited access to intravitreal treatments due to a maldistribution of the ophthalmology workforce. To improve access, a novel outreach service model was implemented whereby junior medical staff administered intravitreal injections under a supervising ophthalmology consultant.
Jackson Chee Chea Lee +4 more
wiley +1 more source